• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环糊精模板化尺寸可调的罗丹明6G纳米胶束增强的化疗毒性

Enhanced chemotherapeutic toxicity of cyclodextrin templated size-tunable rhodamine 6G nanoGUMBOS.

作者信息

Bhattarai Nimisha, Chen Mi, Pérez Rocío L, Ravula Sudhir, Chhotaray Pratap, Hamdan Suzana, McDonough Karen, Tiwari Suman, Warner Isiah M

机构信息

Department of Chemistry, Louisiana State University, Baton Rouge, LA 70803, USA.

出版信息

J Mater Chem B. 2018 Sep 14;6(34):5451-5459. doi: 10.1039/c8tb01115j. Epub 2018 Aug 20.

DOI:10.1039/c8tb01115j
PMID:32254604
Abstract

Nanodrugs have been widely investigated for combating the large number of side effects associated with conventional therapeutics. Several investigations of such nanomedicines have demonstrated the profound role of nanoparticle size in therapeutic efficacy. Herein, we report the role of cyclodextrin (CD)-templating on the size and therapeutic properties of rhodamine 6G (R6G) nanoGUMBOS, i.e. nanomaterials derived from a Group of Uniform Materials Based on Organic Salts (GUMBOS). In these studies, templating of nanoGUMBOS using 2-hydroxypropyl-alpha (2-HP-α), 2-hydroxypropyl beta (2-HP-β), and gamma (γ) cyclodextrin (CD) led to a significant reduction in size and enhanced uniformity as indicated by transmission electron microscopy (TEM) images. In addition, CD-templated nanoGUMBOS remarkably displayed a three to four fold enhancement in toxicity towards cancer cells as compared to nanoGUMBOS without CD-templates, suggesting a significant improvement in therapeutic efficacy. Correlation between size and toxicity suggests that CD-templated nanoparticles of ∼70 to 80 nm produced optimal toxicity. Even more interesting, all investigated nanoGUMBOS displayed no toxicity toward normal cells under examined conditions. Moreover, these nanoGUMBOS display comparable chemotherapeutic toxicity to the parent dye, [R6G][Cl], while also eliminating toxicity towards normal cells, indicating their strong chemotherapeutic potential. The studies outlined here provide further insight into an approach that may be employed for rapid synthesis of size tunable nanodrugs for enhanced chemotherapeutic efficacy.

摘要

纳米药物已被广泛研究,以对抗与传统疗法相关的大量副作用。对这类纳米药物的多项研究表明了纳米颗粒大小在治疗效果中的重要作用。在此,我们报告了环糊精(CD)模板对若丹明6G(R6G)纳米GUMBOS(即基于有机盐的一组均匀材料衍生的纳米材料)大小和治疗特性的作用。在这些研究中,使用2-羟丙基-α(2-HP-α)、2-羟丙基-β(2-HP-β)和γ(γ)环糊精(CD)对纳米GUMBOS进行模板化,导致其尺寸显著减小且均匀性增强,这在透射电子显微镜(TEM)图像中得到了体现。此外,与没有CD模板的纳米GUMBOS相比,CD模板化的纳米GUMBOS对癌细胞的毒性显著提高了三到四倍,表明治疗效果有了显著改善。尺寸与毒性之间的相关性表明,约70至80纳米的CD模板化纳米颗粒产生了最佳毒性。更有趣的是,在检测条件下,所有研究的纳米GUMBOS对正常细胞均无毒性。此外,这些纳米GUMBOS与母体染料[R6G][Cl]具有相当的化疗毒性,同时还消除了对正常细胞的毒性,表明它们具有强大的化疗潜力。此处概述的研究为一种可用于快速合成尺寸可调的纳米药物以提高化疗效果的方法提供了进一步的见解。

相似文献

1
Enhanced chemotherapeutic toxicity of cyclodextrin templated size-tunable rhodamine 6G nanoGUMBOS.环糊精模板化尺寸可调的罗丹明6G纳米胶束增强的化疗毒性
J Mater Chem B. 2018 Sep 14;6(34):5451-5459. doi: 10.1039/c8tb01115j. Epub 2018 Aug 20.
2
Comparison of Chemotherapeutic Activities of Rhodamine-Based GUMBOS and NanoGUMBOS.基于罗丹明的 GUMBOS 和纳米 GUMBOS 的化疗活性比较。
Molecules. 2020 Jul 17;25(14):3272. doi: 10.3390/molecules25143272.
3
Endocytic Selective Toxicity of Rhodamine 6G nanoGUMBOS in Breast Cancer Cells.Rhodamine 6G nanoGUMBOS 在乳腺癌细胞中的内吞选择性毒性。
Mol Pharm. 2018 Sep 4;15(9):3837-3845. doi: 10.1021/acs.molpharmaceut.8b00339. Epub 2018 Jul 27.
4
Mitochondria targeting IR780-based nanoGUMBOS for enhanced selective toxicity towards cancer cells.靶向线粒体的基于IR780的纳米GUMBOS对癌细胞的选择性毒性增强
RSC Adv. 2018 Sep 12;8(55):31700-31709. doi: 10.1039/c8ra05484c. eCollection 2018 Sep 5.
5
Tumor-Targeting NIRF NanoGUMBOS with Cyclodextrin-Enhanced Chemo/Photothermal Antitumor Activities.载环糊精的近红外光响应纳米 GUMBOS 用于增强化疗/光热抗肿瘤活性的研究
ACS Appl Mater Interfaces. 2019 Aug 7;11(31):27548-27557. doi: 10.1021/acsami.9b08047. Epub 2019 Jul 26.
6
Strategies for controlled synthesis of nanoparticles derived from a group of uniform materials based on organic salts.基于有机盐的一组均匀材料衍生的纳米颗粒的可控合成策略。
J Colloid Interface Sci. 2015 May 15;446:163-9. doi: 10.1016/j.jcis.2015.01.023. Epub 2015 Jan 22.
7
Nontemplated approach to tuning the spectral properties of cyanine-based fluorescent nanoGUMBOS.非模板化方法调谐基于菁染料的荧光纳 GUMBOS 的光谱性质。
Langmuir. 2010 Aug 3;26(15):12867-76. doi: 10.1021/la101463r.
8
Tunable size and spectral properties of fluorescent nanoGUMBOS in modified sodium deoxycholate hydrogels.在改性脱氧胆酸钠水凝胶中可调谐荧光纳 Gumbo 的尺寸和光谱性质。
Langmuir. 2012 Jan 10;28(1):757-65. doi: 10.1021/la2027016. Epub 2011 Dec 12.
9
GUMBOS and nanoGUMBOS in chemical and biological analysis: A review.胶态金和纳米胶态金在化学和生物分析中的应用:综述。
Anal Chim Acta. 2020 Oct 9;1133:180-198. doi: 10.1016/j.aca.2020.06.028. Epub 2020 Jul 9.
10
Ultrafast and nonlinear spectroscopy of brilliant green-based nanoGUMBOS with enhanced near-infrared emission.基于灿烂绿的纳米 GUMBOS 的超快和非线性光谱学,具有增强的近红外发射。
J Chem Phys. 2017 Oct 14;147(14):144701. doi: 10.1063/1.4994712.

引用本文的文献

1
Potential of a CO-Responsive supramolecular drug-carrier system as a safer and more effective treatment for cancer.一种对一氧化碳有反应的超分子药物载体系统作为癌症更安全、更有效治疗方法的潜力。
Mater Today Bio. 2024 Oct 29;29:101319. doi: 10.1016/j.mtbio.2024.101319. eCollection 2024 Dec.
2
Interrogating the Role of Endocytosis Pathway and Organelle Trafficking for Doxorubicin-Based Combination Ionic Nanomedicines.探讨基于阿霉素的离子型纳米药物中内吞作用途径和细胞器运输的作用。
ACS Appl Bio Mater. 2024 Aug 19;7(8):5359-5368. doi: 10.1021/acsabm.4c00552. Epub 2024 Aug 5.
3
A CO-Responsive Imidazole-Functionalized Fluorescent Material Mediates Cancer Chemotherapy.
一种对一氧化碳有响应的咪唑功能化荧光材料介导癌症化疗。
Pharmaceutics. 2023 Jan 20;15(2):354. doi: 10.3390/pharmaceutics15020354.
4
Complementary Nucleobase Interactions Drive Co-Assembly of Drugs and Nanocarriers for Selective Cancer Chemotherapy.互补核碱基相互作用驱动药物与纳米载体共同组装用于选择性癌症化疗。
Pharmaceutics. 2021 Nov 15;13(11):1929. doi: 10.3390/pharmaceutics13111929.